Table 1.
Patient characteristics based on donor type.
| Characteristics | MSD | 8/8MUD | 7/8MMUD | UCB | P value |
|---|---|---|---|---|---|
| Number of patients | 214 | 562 | 334 | 677 | |
| Median recipient age (IQR), years | 58 (54–61) | 62 (57–65) | 61 (56–65) | 64 (58–67) | <0.001 |
| Recipient age category | <0.001 | ||||
| 50–59 years | 131 (61.2) | 196 (34.9) | 130 (38.9) | 206 (30.4) | |
| ≥60 years | 83 (38.8) | 366 (65.1) | 204 (61.1) | 471 (69.6) | |
| Recipient sex | 0.573 | ||||
| Female | 70 (32.7) | 175 (31.2) | 92 (27.5) | 205 (30.3) | |
| Male | 144 (67.3) | 386 (68.8) | 242 (72.5) | 472 (69.7) | |
| Missing | 0 | 1 | 0 | 0 | |
| PS | 0.018 | ||||
| 0–1 | 195 (91.1) | 533 (95.0) | 315 (94.3) | 614 (90.8) | |
| 2–4 | 19 (8.9) | 28 (5.0) | 19 (5.7) | 62 (9.2) | |
| Missing | 0 | 1 | 0 | 1 | |
| HCT-CI | 0.142 | ||||
| 0–2 | 163 (76.5) | 418 (74.6) | 263 (78.7) | 489 (72.2) | |
| ≥3 | 50 (23.5) | 142 (25.4) | 71 (21.3) | 188 (27.8) | |
| Missing | 1 | 2 | 0 | 0 | |
| Recipient CMV serostatus | 0.317 | ||||
| Negative | 31 (15.1) | 67 (12.1) | 46 (14.5) | 73 (11.2) | |
| Positive | 174 (84.9) | 485 (87.9) | 272 (85.5) | 581 (88.8) | |
| Missing | 9 | 10 | 16 | 23 | |
| MDS etiology | 0.218 | ||||
| De novo | 191 (89.3) | 483 (85.9) | 299 (89.5) | 579 (85.7) | |
| Secondary | 23 (10.7) | 79 (14.1) | 35 (10.5) | 97 (14.3) | |
| Missing | 0 | 0 | 0 | 1 | |
| Karyotype | 0.165 | ||||
| Good | 82 (39.6) | 206 (37.3) | 126 (38.2) | 220 (33.3) | |
| Intermediate | 33 (15.9) | 119 (21.6) | 55 (16.7) | 128 (19.4) | |
| Poor | 92 (44.4) | 227 (41.1) | 149 (45.2) | 312 (47.3) | |
| Missing | 7 | 10 | 4 | 7 | |
| IPSS at diagnosis | 0.278 | ||||
| Low | 12 (5.8) | 30 (5.6) | 19 (5.8) | 42 (6.5) | |
| Intermediate-1 | 58 (28.2) | 176 (33.1) | 97 (29.7) | 161 (25.0) | |
| Intermediate-2 | 83 (40.3) | 188 (35.4) | 124 (37.9) | 248 (38.4) | |
| High | 53 (25.7) | 137 (25.8) | 87 (26.6) | 194 (30.1) | |
| Missing | 8 | 31 | 7 | 32 | |
| WHO classification at HCT | 0.604 | ||||
| RA, SLD | 9 (4.2) | 32 (5.7) | 15 (4.5) | 29 (4.3) | |
| RARS, RS-SLD, RS-MLD | 5 (2.3) | 19 (3.4) | 12 (3.6) | 32 (4.7) | |
| RCMD, MLD | 46 (21.5) | 121 (21.5) | 64 (19.2) | 128 (18.9) | |
| MDS-U | 8 (3.7) | 22 (3.9) | 21 (6.3) | 19 (2.8) | |
| MDS with isolated del(5q) | 0 | 1 (0.2) | 0 | 3 (0.4) | |
| RAEB-1, EB-1 | 68 (31.8) | 151 (26.9) | 105 (31.4) | 194 (28.7) | |
| RAEB-2, EB-2 | 75 (35.0) | 209 (37.2) | 113 (33.8) | 265 (39.1) | |
| Others | 2 (0.9) | 5 (0.9) | 2 (0.6) | 6 (0.9) | |
| Missing | 1 (0.5) | 2 (0.4) | 2 (0.6) | 1 (0.1) | |
| Disease risk at HCT | 0.617 | ||||
| Low-risk | 68 (32.2) | 195 (35.1) | 112 (33.9) | 213 (31.7) | |
| High-risk | 143 (67.8) | 360 (64.9) | 218 (66.1) | 459 (68.3) | |
| Missing | 3 | 7 | 4 | 5 | |
| Diagnosis to HCT | <0.001 | ||||
| <6 months | 19 (8.9) | 4 (0.7) | 1 (0.3) | 97 (14.4) | |
| 6–12 months | 89 (41.6) | 158 (28.2) | 79 (23.7) | 210 (31.1) | |
| ≥12 months | 106 (49.5) | 399 (71.1) | 254 (76.0) | 368 (54.5) | |
| Missing | 0 | 1 | 0 | 2 | |
| Previous treatment of azacitidine | 0.024 | ||||
| No | 126 (58.9) | 264 (47.0) | 160 (47.9) | 342 (50.6) | |
| Yes | 88 (41.1) | 298 (53.0) | 174 (52.1) | 334 (49.4) | |
| Missing | 0 | 0 | 0 | 1 | |
| Previous treatment of chemotherapy | 0.732 | ||||
| No | 149 (69.6) | 414 (73.7) | 243 (72.8) | 489 (72.3) | |
| Yes | 65 (30.4) | 148 (26.3) | 91 (27.2) | 187 (27.7) | |
| Missing | 0 | 0 | 0 | 1 | |
| Previous treatment of immunosuppression | 0.075 | ||||
| No | 203 (94.9) | 515 (91.6) | 317 (94.9) | 641 (94.8) | |
| Yes | 11 (5.1) | 47 (8.4) | 17 (5.1) | 35 (5.2) | |
| Missing | 0 | 0 | 0 | 1 | |
| Graft source | <0.001 | ||||
| BM | 55 (25.7) | 465 (82.7) | 295 (88.3) | 0 | |
| PBSC | 159 (74.3) | 97 (17.3) | 39 (11.7) | 0 | |
| CB | 0 | 0 | 0 | 677 (100.0) | |
| Median donor age (IQR), years | 57 (53–60) | 40 (33–45) | 40 (32–45) | 0 | <0.001 |
| Donor sex | |||||
| Female | 101 (47.2) | 152 (27.0) | 88 (26.4) | 343 (51.0) | <0.001 |
| Male | 113 (52.8) | 410 (73.0) | 245 (73.6) | 329 (49.0) | |
| Missing | 0 | 0 | 1 | 5 | |
| Sex incompatibility | <0.001 | ||||
| Female to male | 67 (31.3) | 95 (16.9) | 66 (19.8) | 247 (36.8) | |
| Others | 147 (68.7) | 466 (83.1) | 267 (80.2) | 425 (63.2) | |
| Missing | 0 | 1 | 1 | 5 | |
| ABO incompatibility | <0.001 | ||||
| Match/minor mismatch | 165 (77.5) | 411 (73.4) | 231 (69.2) | 411 (61.2) | |
| Major/bidirectional mismatch | 48 (22.5) | 149 (26.6) | 103 (30.8) | 261 (38.8) | |
| Missing | 1 | 2 | 0 | 5 | |
| Conditioning regimen | <0.001 | ||||
| MAC | 140 (65.4) | 340 (60.5) | 189 (56.6) | 346 (51.1) | |
| RIC | 74 (34.6) | 222 (39.5) | 145 (43.4) | 331 (48.9) | |
| GVHD prophylaxis | <0.001 | ||||
| CI + MTX | 201 (93.9) | 525 (93.6) | 311 (93.1) | 386 (57.2) | |
| CI + MMF | 9 (4.2) | 25 (4.5) | 12 (3.6) | 255 (37.8) | |
| Others | 4 (1.9) | 11 (2.0) | 11 (3.3) | 34 (5.0) | |
| Missing | 0 | 1 | 0 | 2 | |
| Use of ATG | <0.001 | ||||
| No | 195 (91.1) | 518 (92.2) | 241 (72.2) | 645 (95.3) | |
| Yes | 19 (8.9) | 44 (7.8) | 93 (27.8) | 32 (4.7) | |
| Median follow-up for survivors (IQR), months | 36 (17–53) | 28 (13–50) | 28 (12–50) | 27 (12–47) | 0.058 |
IQR interquartile range, PS performance status, HCT-CI hematopoietic cell transplantation-specific comorbidity index, CMV cytomegalovirus, MDS myelodysplastic syndrome, IPSS international prognostic scoring system, WHO World Health Organization, HCT hematopoietic cell transplantation, RA refractory anemia, SLD single lineage dysplasia, RARS refractory anemia with ringed sideroblasts, RS-SLD ringed sideroblasts with single lineage dysplasia, RS-MLD ringed sideroblasts with multilineage dysplasia, RCMD refractory cytopenia with multilineage dysplasia, MLD multilineage dysplasia, MDS-U MDS unclassifiable, RAEB refractory anemia with an excess of blasts, EB excess blasts, BM bone marrow, PBSC peripheral blood stem cell, CB cord blood, MAC myeloablative conditioning, RIC reduced-intensity conditioning, GVHD graft-versus-host disease, CI calcineurin inhibitor, MTX methotrexate, MMF Mycophenolate mofetil, ATG antithymocyte globulin, MSD matched sibling donor, MUD matched unrelated donor, UCB unrelated cord blood.
The P values in bold are statistically significant (<0.05).